Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Repare Therapeutics Inc./ 15-12G

SEC Filing · 15-12G

Repare Therapeutics Inc.

SEC Filing

Filed Feb 19, 2026Accepted Feb 18, 2026, 4:36 PM ESTCIK 1808158Accession 0001193125-26-057875
View company →Permanent SEC source ↗
Share

Company context

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polq ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor.

Recent company filings

  1. SCHEDULE 13G/A - filed by Blue Owl Capital Holdings LP regarding Repare Therapeutics Inc.May 14, 2026
  2. EFFECT filingJan 30, 2026
  3. 4 filingJan 28, 2026
  4. 4 filingJan 28, 2026
  5. 4 filingJan 28, 2026

As-filed source

Primary evidence
As filedOpen full document ↗